Real-world data contrasts clinical trial results for pertuzumab and T-DM1 in HER2+ breast cancer

Written by Darcy Hodge, Editor

breast cancer treatment pertuzumab T-DM1

Real-world evidence published in JAMA Oncology, led by researchers at Queen’s University (Kingston, Canada), has determined that practical use of pertuzumab and trastuzumab emtansine in the treatment of metastatic breast cancers lacks effectiveness, unlike previous clinical studies. A retrospective real-world analysis of 795 participants with metastatic breast cancer has determined that pertuzumab and trastuzumab emtansine may not lead to improved overall survival rates. This contrasts from two previous studies deemed as successful in determining viable treatments for metastatic breast cancer – CLEOPATRA in 2012 and EMILIA in 2013. Josee-Lyne Ethier (Queen’s University), lead author of the investigation, noted clinical trials...

To view this content, please register now for access

It's completely free